Related Experiment Video
Updated: Sep 19, 2025
Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
Published on: October 2, 2020
Claudin-6 mediates an embryonic stem cell-driven antitumor response against breast cancer
Magda Correia1, Carlota Tavares-Marcos1, João Pessoa1
1Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal.
Abstract:
Stem cells are emerging sources of antigens for cancer immunotherapy. Here, we used TNG-A mouse embryonic stem cells to trigger an anticancer response against tumors derived from E0771 mouse breast cancer cells, possibly mediated by the mouse immune system. TNG-A cells were cultured in the presence or absence of two specific kinase inhibitors. While the inhibitors preserved TNG-A pluripotency, their removal altered the morphology, transcriptome, and proteome of TNG-A cells, increasing their similarities with E0771 cancer cells. Double pre-exposure by subcutaneous injection of TNG-A cells followed by E0771 implantation drastically decreased E0771-derived tumor size in mice. Serum cytokine quantifications suggested a transient immune reaction associated with tumor regression. Nevertheless, pre-exposure to TNG-A cells impaired for the tight junction protein Claudin 6 failed to decrease tumor size. Our findings demonstrate the anti-tumor effects of embryonic stem cells and anticipate their potential as an allogenic source for cancer immunotherapy.
Insights
Embryonic stem cells show potential for cancer immunotherapy. Pre-exposure to modified TNG-A stem cells reduced tumor size in mice, suggesting a novel approach to cancer treatment.
Area of Science:
- Immunology
- Stem Cell Biology
- Oncology
Background:
- Embryonic stem cells (ESCs) are increasingly recognized as potential sources of antigens for cancer immunotherapy.
- The study investigates the immunomodulatory properties of TNG-A mouse ESCs against E0771 mouse breast cancer.
Purpose of the Study:
- To evaluate the anti-tumor effects of ESCs as a potential allogeneic cancer immunotherapy.
- To explore the role of specific modifications in ESCs on their anti-cancer efficacy.
Main Methods:
- TNG-A ESCs were cultured with or without kinase inhibitors, altering their characteristics.
- Mice were pre-exposed to modified TNG-A cells before implantation with E0771 breast cancer cells.
- Tumor size, serum cytokine levels, and the expression of Claudin 6 were analyzed.
Main Results:
- Pre-exposure to modified TNG-A cells significantly reduced E0771 tumor size in mice.
- A transient immune reaction, indicated by serum cytokines, correlated with tumor regression.
- ESCs lacking functional Claudin 6 did not elicit the same anti-tumor effect, highlighting the importance of specific cellular components.
Conclusions:
- Embryonic stem cells possess demonstrable anti-tumor effects.
- Modified ESCs show promise as an allogeneic source for cancer immunotherapy.
- The integrity of specific proteins like Claudin 6 is crucial for ESC-mediated anti-cancer responses.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:23Renewal of Intestinal Stem Cells
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...